Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about ARIA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Cerebral Amyloid Angiopathy | associated_with | disease | 0.80 |
| accelerated amyloid clearance | associated_with | process | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| anti-amyloid antibody therapy | causes | drug | 0.90 |
| Amyloid-Beta Aggregation | mediates | process | 0.80 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 6 hypotheses Top: 0.886
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| NAD depletion effects on monocyte/macrophage differentiation | exploratory | Inflammatory bowel disease | 0.900 | 0.00 | Primary mouse and human monocy | proposed | N/A |
| FK866 treatment in DSS-induced colitis mouse model | validation | Inflammatory bowel disease (co | 0.900 | 0.00 | DSS-induced colitis mice | proposed | N/A |
| FK866 in azoxymethane/DSS colitis-associated cancer model | validation | Colitis-associated cancer | 0.850 | 0.00 | AOM/DSS-treated mice | proposed | N/A |
| FK866 mechanism validation in Rag1-/- mice | validation | Inflammatory bowel disease | 0.850 | 0.00 | Rag1-/- mice with DSS-induced | proposed | N/A |
| CHI3L1 variant association with AD progression in human patients | exploratory | Alzheimer's disease | 0.850 | 0.00 | human patients | proposed | N/A |
| Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Computational Modeling of Alpha-Synuclein Propagation in PD | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Alpha-Synuclein Seed Amplification Assay Validation | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Antiviral Therapy Trial for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Combination Therapy Sequencing in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Genetic Risk Modifiers in DLB Phenotype | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $7,500,000 |
| DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibito | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| Endocannabinoid System Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmaco [PMID:34106485] | Cacabelos R, Carrera I, Martínez O, Alej | Med Res Rev | 2021 | 1 |
| Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation [PMID:31120439] | Luo Z, Ahlers-Dannen KE, Spicer MM, Yang | JCI Insight | 2019 | 1 |
| Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant [PMID:31873106] | Yedlapudi D, Xu L, Luo D, Marsh GB, Todi | Sci Rep | 2019 | 1 |
| A systematic review and integrative approach to decode the common molecular link [PMID:28927418] | Guin D, Mishra MK, Talwar P, Rawat C, Ku | BMC Med Genomics | 2017 | 1 |
| The role of genetic factors in the occurrence of levodopa-induced motor complica [PMID:40632937] | ["Radojevi\u0107 B", "Milovanovi\u0107 A | Neurological research | 2026 | 0 |
| The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease [PMID:41109213] | Pilat DJ, Le H, Prokopenko D, Lin CJ, Ei | Neuron | 2026 | 0 |
| Role of TREM2 in neuroinflammation. [PMID:41213496] | Abdulkhaliq AA, Alasiri G, Almoghrabi Y, | Exp Neurol | 2026 | 0 |
| Synergistic potential of TREM2 agonists and exercise training in Alzheimer's dis [PMID:41494649] | Zhang J, St Pierre Schneider B, Muguerza | Am J Physiol Endocrinol Metab | 2026 | 0 |
| Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvir [PMID:41576929] | Mateus-Tique J, Lakshmi A, Singh B, Iyer | Cancer Cell | 2026 | 0 |
| Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952] | Li X, Tang X, Zeng J, Duan L, Hou Z et a | Cell | 2026 | 0 |
| TREM2 expression level is critical for microglial state, metabolic capacity and [PMID:41580393] | Feiten AF, Dahm K, Schlepckow K, van Len | Nat Commun | 2026 | 0 |
| Large-scale single-cell analysis and in silico perturbation reveal dynamic evolu [PMID:41617928] | Xia P, Shuang S, Fu D, Liu L, Yang D et | NPJ Precis Oncol | 2026 | 0 |
| Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant [PMID:41720086] | Zhao Q, Huang R, Wang C, Hu J, Nie R et | Cancer Cell | 2026 | 0 |
| TREM2 in neurodegeneration and diseases. [PMID:41792456] | ["Abdulkhaliq A", "Alasiri G", "Kim B", | Molecular psychiatry | 2026 | 0 |
| Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation. [PMID:41745721] | Aranda-Abreu GE, Rojas-Durán F, Hernánde | Neurology international | 2026 | 0 |
| Molecular mechanism of Alzheimer's disease using integrated multi-omics. [PMID:41907842] | Alhusaini M, Mussa BM, Ilce BY, Alhaj H, | Frontiers in aging neuroscienc | 2026 | 0 |
| Reliability and Discriminant Ability of an Instrumented Timed Up and Go Test in [PMID:41921127] | ["Giardini M", "Arcolin I", "Arcobelli V | JMIR rehabilitation and assist | 2026 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| Evaluating the Utility of Wearable Sensors for the Early Diagnosis of Parkinson [PMID:40690754] | ["Li H", "Zecca M", "Huang J"] | Journal of medical Internet re | 2025 | 0 |
| Viral and non-viral cellular therapies for neurodegeneration. [PMID:41585268] | ["Srivastav Jyotsna", "Sharma Sachin"] | Frontiers in medicine | 2025 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.50 · 2026-04-26
closed · Rounds: 4 · Score: 0.50 · 2026-04-26
closed · Rounds: 4 · Score: 0.57 · 2026-04-01
Hypotheses and analyses mentioning ARIA in their description or question text
Score: 0.626 · neurodegeneration · 2026-04-28
PD genetic aging variants accelerating cell-type-specific epigenetic clock trajectories should produce a measurable prox
Score: 0.612 · neurodegeneration · 2026-04-28
The question is likely underpowered or misleading unless analyses preserve the key strata: PD-. Averaging across these s
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.435 · protein folding · 2026-04-22
## Mechanistic Overview Seed Conformational Heterogeneity Explains Variable Chaperone Susceptibility—Strain-Specific Tar
Score: 0.380 · Late-onset Alzheimer's disease · 2026-04-26
We hypothesize that rare loss-of-function variants in microglial-expressed genes within the TREM2-TYROBP signaling casca
Score: 0.380 · Alzheimer's disease · 2026-04-26
Bayesian fine-mapping of the top 25 AD GWAS loci will identify credible sets significantly enriched for variants disrupt
Score: 0.335 · unknown disease · 2026-04-26
CSF p-tau217 levels reflect a dynamic equilibrium between neuronal tau release and CSF clearance, with significant inter
Score: 0.311 · synaptic biology · 2026-04-21
## Mechanistic Overview Partial Agonist/SPP1 Splice Variant Strategy: Splice-Switching Therapeutics starts from the clai